Affordable Access

Access to the full text

Effects of Amifostine in Combination With Cyclophosphamide on Female Reproductive System

Authors
  • Barekati, Zeinab1, 2
  • Golkar-Narenji, Afsaneh1
  • Totonchi, Mehdi1
  • Radpour, Ramin2
  • Gourabi, Hamid1
  • 1 Royan Institute, ACECR, Tehran, Iran , Tehran (Iran)
  • 2 University of Basel, Switzerland , (Switzerland)
Type
Published Article
Journal
Reproductive Sciences
Publisher
SAGE Publications
Publication Date
May 01, 2012
Volume
19
Issue
5
Pages
539–546
Identifiers
DOI: 10.1177/1933719111426599
Source
Springer Nature
Keywords
License
Yellow

Abstract

This study investigated the cytoprotective effects of amifostine against the adverse effects of cyclophosphamide relying on ovarian cell death markers and the fertilization rate of the surviving follicles as a late outcome of the study. Combined pretreatment of amifostine with cyclophosphamide enabled partial recovery of antiapoptotic messenger RNA (mRNA) expression levels while a decrease in expression of BAX and Casp3 were identified. The pretreatment of amifostine to cyclophosphamide significantly reduced the proportion of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive primary and preantral follicles (P < .001 and P < .05, respectively). These findings were comparable with the results obtained from protein expression of cleaved caspase 3. The fertilization rate showed a significant capability of amifostine to improve fertilization potency of oocytes exposed to cyclophosphamide (P < .01). In conclusion, administration of amifostine prior to cyclophosphamide might serve as a promising protocol to improve female fertility.

Report this publication

Statistics

Seen <100 times